Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response

Simmons, Bryony; Saleem, Jawaad; Heath, Katherine; Cooke, Graham; Hill, Andrew

doi:10.1093/cid/civ396

Cited by 233 publications

(198 citation statements)

References 54 publications

Supporting

Mentioning

183

Contrasting

Unclassified

Order By: Relevance

“…S3 and S4). Studies on interferon and ribavirin treatment for chronic HCV infection have reported that all-cause mortality rates for patients with a sustained virological response-which equates to cure in nearly all cases-are not statistically different from those of an age-matched general population (12)(13)(14). Therefore, we used general-population mortality rates as a proxy for patients who receive new HCV-directed therapies (15,16).…”

Section: Simulating An Hcl Fundmentioning

confidence: 99%

Buying cures versus renting health: Financing health care with consumer loans

Montazerhodjat¹,

Weinstock

Lo³

2016

Sci. Transl. Med.

View full text Add to dashboard Cite

A crisis is building over the prices of new transformative therapies for cancer, hepatitis C virus infection, and rare diseases. The clinical imperative is to offer these therapies as broadly and rapidly as possible. We propose a practical way to increase drug affordability through health care loans (HCLs)-the equivalent of mortgages for large health care expenses. HCLs allow patients in both multipayer and single-payer markets to access a broader set of therapeutics, including expensive short-duration treatments that are curative. HCLs also link payment to clinical benefit and should help lower per-patient cost while incentivizing the development of transformative therapies rather than those that offer small incremental advances. Moreover, we propose the use of securitization-a well-known financial engineering method-to finance a large diversified pool of HCLs through both debt and equity. Numerical simulations suggest that securitization is viable for a wide range of economic environments and cost parameters, allowing a much broader patient population to access transformative therapies while also aligning the interests of patients, payers, and the pharmaceutical industry.

show abstract

Section: Simulating An Hcl Fundmentioning

confidence: 99%

Buying cures versus renting health: Financing health care with consumer loans

Montazerhodjat¹,

Weinstock

Lo³

2016

Sci. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…It is notable that groups B and C might include patients without chronic liver diseases before the occurrence of HCC. Nevertheless, when focusing only on effects in viral-related cases, group A comprised of more patients with a history of anti-viral therapy and had a more advantageous hepatic reserve (13,14). Moreover, an earlier stage of HCC and stable hepatic reserve, which were related with regular hospital visits before occurrence of HCC, might be more amenable to curative initial treatments for HCC and contribute to an improved prognosis after the diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Regular hospital visits improve the prognosis of hepatocellular carcinoma after initial diagnosis: A single regional community hospital study

Watanabe

Yomokori²,

Takahashi³

et al. 2017

Turk J Gastroenterol

View full text Add to dashboard Cite

“…A meta-analysis study examined the survival benefit of achieving SVR, looking at a total of 33,360 patients with HCV and HIV/HCV coinfection [31]. Achieving HCV SVR was associated with a 50% reduction in the risk of all-cause mortality compared with not achieving SVR in the general HCV population.…”

Section: Coinfection With Hivmentioning

confidence: 99%

A Brief Update on the Treatment of Hepatitis C

Austria¹,

Ninčević²,

Wu³

2017

Update on Hepatitis C

View full text Add to dashboard Cite

Hepatitis C virus was discovered nearly 30 years ago, and for the first two decades, treatment was limited to agents with low response rates and substantial side effects. Since the introduction of direct-acting antivirals, there have been rapid advances made toward even higher sustained virologic responses (SVRs) and fewer side effects. This chapter provides a review of the newer agents for treatment of hepatitis C and highlights special populations, including those coinfected with HIV or hepatitis B, previously treated patients, and post-liver transplant patients.

show abstract

Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response

Cited by 233 publications

References 54 publications

Buying cures versus renting health: Financing health care with consumer loans

Buying cures versus renting health: Financing health care with consumer loans

Regular hospital visits improve the prognosis of hepatocellular carcinoma after initial diagnosis: A single regional community hospital study

A Brief Update on the Treatment of Hepatitis C

Contact Info

Product

Resources

About